Tagged indevr

InDevR Launches Highly Multiplexed Kit for Rapid Pneumococcal Vaccine Characterization
Press Release

InDevR Launches Highly Multiplexed Kit for Rapid Pneumococcal Vaccine Characterization

 Read More
InDevR Launches ArrayMax Mixer for Even Faster VaxArray Assay Times
Press Release

InDevR Launches ArrayMax Mixer for Even Faster VaxArray Assay Times

 Read More
InDevR Launches VaxArray Polio Kit for Faster, Multiplexed Vaccine Characterization
Press Release

InDevR Launches VaxArray Polio Kit for Faster, Multiplexed Vaccine Characterization

 Read More
InDevR Launches VaxArray Measles and Rubella Kit for Improved Vaccine Antigen Characterization
Press Release

InDevR Launches VaxArray Measles and Rubella Kit for Improved Vaccine Antigen Characterization

 Read More
InDevR Ships First Multiplexed COVID-19 Serology Test Kits for Clinical Validation
Press Release

InDevR Ships First Multiplexed COVID-19 Serology Test Kits for Clinical Validation

 Read More
Terry Salyer Joins InDevR as Chief Commercial Officer
Press Release

Terry Salyer Joins InDevR as Chief Commercial Officer

 Read More
Barry Buckland Joins InDevR's Board of Directors
Press Release

Barry Buckland Joins InDevR's Board of Directors

 Read More
InDevR Raises $7 Million in Series A Financing With Adjuvant Capital
Press Release

InDevR Raises $7 Million in Series A Financing With Adjuvant Capital

 Read More
InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray® Neuraminidase Potency Assay
Press Release

InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray® Neuraminidase Potency Assay

Panel of antibodies developed at Mount Sinai will enable first multiplexed potency assay for tracking neuraminidase in flu vaccines.

 Read More